<DOC>
	<DOCNO>NCT00831896</DOCNO>
	<brief_summary>This study multicenter , open-label , dose escalation , phase 1 study TAK 701 adult patient advance nonhematologic malignancy . This study first administer TAK 701 human . The primary purpose study determine safety profile , tolerability , pharmacokinetics profile TAK-701 .</brief_summary>
	<brief_title>Phase I Study TAK-701 Adult Patients With Advanced Nonhematological Malignancies</brief_title>
	<detailed_description />
	<criteria>1 . Male female patient age 18 year old . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 3 . Diagnosis nonhematologic malignancy standard curative lifeprolonging treatment exist longer effective . 4 . Radiographically clinically evaluable tumor ; however , measurable disease require participation study ( eg , patient pleural effusion ascites ) . 5 . Female patient : Are postmenopausal least 1 year screen visit , Are surgically sterile , If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 3 month last dose study drug , agree completely abstain heterosexual intercourse . Male patient , even surgically sterilize ( ie , status postvasectomy ) , : Agree practice effective barrier contraception entire study drug treatment period 3 month last dose TAK701 , Agree completely abstain heterosexual intercourse . 6 . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . 1 . Female patient lactate positive serum pregnancy test screening period . 2 . Major surgery within 14 day first dose TAK701 planned/anticipated surgery study period . 3 . Positive test Hepatitis B C infection . 4 . Active alcohol abuse 5 . Active infection require systemic therapy , serious infection . 6 . Antineoplastic therapy ( include unconjugated therapeutic antibody toxin immunoconjugates ) experimental therapy within 21 day first dose TAK701 . 7 . Radiotherapy within 21 day first dose TAK701 . 8 . Nitrosoureas mitomycinC within 6 week first dose TAK701 . 9 . Autologous stem cell transplant within 3 month first dose TAK701 , prior allogeneic stem cell transplant time . 10 . Any prior exposure antiHGF therapy ( eg , AMG102 , AV299 ) . 11 . The patient symptomatic brain metastasis . 12 . Absolute neutrophil count &lt; 1,500/mm3 ; platelet count &lt; 100,000/mm3 . 13 . Calculated creatinine clearance &lt; 50mL/minute 14 . Any following clinical laboratory result screen ( ie , within 28 day first dose TAK701 ) : Bilirubin &gt; 1.5 time upper limit normal range ( ULN ) . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time ULN . AST ALT may elevate 5 time ULN elevation reasonably ascribe presence metastatic disease liver and/or bone . 15 . Known human immunodeficiency virus ( HIV ) positive . 16 . Serious medical psychiatric illness likely interfere participation clinical study . 17 . Uncontrolled cardiovascular condition , include ongoing cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month . 18 . Patients QTc &gt; 470 msec 12lead ECG obtain within 28 day first study drug administration . 19 . Presence serious nonhealing wound , ulcer bone fracture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>